Sign in
Taking people in South KoreaNo phase

Studies people at high risk of developing inflammatory bowel disease

Looks for risk factors in people at high risk of inflammatory bowel disease.

Key facts

Who runs it
Seoul National University Hospital
Where
Seoul, South KoreaSee the site
Trial code
Registry title
SNU IBD Cohort Study : Searching for Characterization of High Risk Populations for Developing Inflammatory Bowel Disease
Status
Recruiting
People taking part
500 people, planned
Started
7 Jan 2022
Planned end
31 Dec 2025
Type of study
Observational
Record updated
10 June 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people at high risk of developing inflammatory bowel disease (IBD). This includes close relatives of IBD patients, people with autoimmune diseases, and some people with stomach and bowel problems who test ASCA-positive.

Age
10 years and older
Sex
All sexes can join.
Disease stage
People who do not have IBD but are at high risk of getting it: first-degree relatives of IBD patients, people with an autoimmune disease, or people with functional gastrointestinal disorders.
Earlier treatment
People with a treatment history of diabetes mellitus, irritable bowel syndrome or colon cancer cannot join.
Biomarker or test result
People with functional gastrointestinal disorders must be ASCA-positive.

Main reasons for not taking part

  • Found to have inflammatory bowel disease on colonoscopy after symptoms such as 10% weight loss within 3 months, abdominal pain, blood in stool or diarrhea
  • Treatment history of diabetes mellitus
  • Treatment history of irritable bowel syndrome
  • Treatment history of colon cancer

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • first-degree relatives of Inflammatory Bowel Disease patients
  • patients who are diagnosed with autoimmune diseases
  • patients with functional gastrointestinal disorders who are ASCA-positive

Who cannot take part

  • Patients with symptoms such as a 10% weight loss within 3 months, abdominal pain, hematochezia, or diarrhea will undergo colonoscopy, and those diagnosed with Inflammatory Bowel Disease will be excluded
  • Treatment history of Diabetes Mellitus, Irritable Bowel Syndrome, or colon cancer

Where in South Korea

  • Seoul National University HospitalSeoul, South KoreaContact: KohTaking people

About the trial

What the trial wants to find out

The goal of this observational study is to investigate characteristics of individuals at high risk for developing Inflammatory Bowel Disease (IBD) in order to identify risk factors associated with its incidence.

Read full original descriptionShow less

The main question it aims to answer is:

What are the risk factors for developing Inflammatory Bowel Disease?

Researchers will compare groups at high risk for IBD to healthy populations and to patients already diagnosed with IBD.

Participants will

* undergo assessments of general demographic and clinical characteristics. * be monitored for symptoms using questionnaires administered at regular intervals. * have blood tests and stool examinations performed. In cases where participants undergo colonoscopy for routine clinical indications, gut biopsies will also be performed.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
SNU IBD Cohort Study : Searching for Characterization of High Risk Populations for Developing Inflammatory Bowel Disease (SNU PREVENT)
Plain-language title
Studies people at high risk of developing inflammatory bowel diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
10 June 2025